Literature DB >> 7516696

Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration.

A J Vora1, C H Toh, J Peel, M Greaves.   

Abstract

Peripheral blood stem cells have been used for autologous reconstitution of haemopoiesis after high dose cytotoxic therapy and produce similar disease response rates as autologous bone marrow transplants. Peripheral blood stem cell transplants are an especially attractive option for patients in whom marrow harvest is not feasible due to bone marrow damage or infiltration. Recombinant growth factors mobilize adequate numbers of stem cells from the marrow but their effect on tumour cell circulation kinetics is not known. We report a patient with multiple myeloma and bone marrow infiltration in whom the use of G-CSF for stem cell mobilization led to release of plasma cells into the peripheral circulation and contamination of the stem cell harvest.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516696     DOI: 10.1111/j.1365-2141.1994.tb03271.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Treatment of multiple myeloma in elderly patients. New developments.

Authors:  G J Ossenkoppele
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 2.  Clinical toxicity of cytokines used as haemopoietic growth factors.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

3.  TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.

Authors:  Isabel Puig; Stephan P Tenbaum; Irene Chicote; Oriol Arqués; Jordi Martínez-Quintanilla; Estefania Cuesta-Borrás; Lorena Ramírez; Pilar Gonzalo; Atenea Soto; Susana Aguilar; Cristina Eguizabal; Ginevra Caratù; Aleix Prat; Guillem Argilés; Stefania Landolfi; Oriol Casanovas; Violeta Serra; Alberto Villanueva; Alicia G Arroyo; Luigi Terracciano; Paolo Nuciforo; Joan Seoane; Juan A Recio; Ana Vivancos; Rodrigo Dienstmann; Josep Tabernero; Héctor G Palmer
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

4.  Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.

Authors:  P Quittet; P Ceballos; E Lopez; Z Y Lu; P Latry; C Becht; E Legouffe; N Fegueux; C Exbrayat; D Pouessel; V Rouillé; J P Daures; B Klein; J F Rossi
Journal:  Bone Marrow Transplant       Date:  2006-08       Impact factor: 5.483

Review 5.  Metastasis prevention by targeting the dormant niche.

Authors:  Cyrus M Ghajar
Journal:  Nat Rev Cancer       Date:  2015-04       Impact factor: 60.716

Review 6.  The dormant cancer cell life cycle.

Authors:  Tri Giang Phan; Peter I Croucher
Journal:  Nat Rev Cancer       Date:  2020-06-02       Impact factor: 60.716

Review 7.  Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.

Authors:  J E Frampton; C R Lee; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 8.  Tumor Dormancy: Biologic and Therapeutic Implications.

Authors:  Vanshika Balayan; Achuta Kumar Guddati
Journal:  World J Oncol       Date:  2022-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.